Your browser doesn't support javascript.
Reduction of Infusion Time Using a 10% Intravenous Immunoglobulin Formulation With a 15-Minute Rate Escalation Protocol During Staffing Shortages Due to COVID-19.
Prosser, Barbara; Walton, Timothy P; Miller, Christine.
  • Prosser B; Soleo Health, Frisco, Texas.
  • Walton TP; Barbara Prosser, RPh, most recently served as the vice president of Health Economics and Outcomes Research at Soleo Health. She spearheaded research and outcome measurement opportunities to provide real-world evidence related to the patient experience and therapy outcomes. Her 35 years of experience
  • Miller C; Timothy P. Walton, MHS, CCRP, is the vice president of Scientific Research and Data Quality at Soleo Health. He manages and monitors health care quality measures, data metrics, data quality, health economics and value strategies, and real-world evidence for prescribers, payers and manufacturers in m
J Infus Nurs ; 45(6): 299-305, 2022.
Article in English | MEDLINE | ID: covidwho-2097523
ABSTRACT
The COVID-19 pandemic changed home infusion nursing dramatically by increasing demand for home infusion nurses while decreasing their availability. Home infusion of intravenous immunoglobulin (IVIg) is an option for treatment of numerous conditions and requires considerable infusion time. Use of a higher-concentration IVIg product and shorter escalation increments may decrease required infusion time. The authors conducted a retrospective database analysis that identified 23 patients receiving IVIg before transitioning to a 10% IVIg product with a 15-minute rate escalation protocol (Gammaplex 10% IVIg) and evaluated the total infusion time before and after the transition. Among the 23 who received IVIg, the mean ± SD IVIg dose per dosing cycle before transitioning was 1.2 ± 0.7 g/kg given in 1 to 5 infusions per cycle. The mean ± SD time per infusion was 2.8 ± 0.8 hours before the transition and 2.6 ± 0.7 hours per infusion after the transition. The infusion time decreased after transition in 13 patients (56.5%), did not change in 5 patients (21.7%), and increased in 5 patients (21.7%). Nurse education on IVIg rate escalation may facilitate faster achievement of the maximum safe infusion rate and reduce infusion times. A trial transition to this 10% IVIg product with a 15-minute rate escalation protocol may also reduce infusion times.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Immunologic Deficiency Syndromes Type of study: Experimental Studies / Observational study / Randomized controlled trials Limits: Humans Language: English Journal: J Infus Nurs Journal subject: Nursing Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Immunologic Deficiency Syndromes Type of study: Experimental Studies / Observational study / Randomized controlled trials Limits: Humans Language: English Journal: J Infus Nurs Journal subject: Nursing Year: 2022 Document Type: Article